A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

Dec. 5, 2024 — Mangroves have been shown to provide $855 billion in flood protection services worldwide, according to a new ... Dec. 4, 2024 — Coconut palms are king throughout the tropics ...

GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to ...

Johnson & Johnson submitted to the FDA trial data that it hopes will lead to the first approved treatment for smoldering myeloma. Also in the news: 3D mammograms gain popularity; companies want to ...

Recent headlines in health news spotlight several pharmaceutical developments: AbbVie's Parkinson's drug shows promise in ...

Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial23 months median Overall Survival from date of ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall ...

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...

GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.